Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) Posts Quarterly Earnings Results, Misses Estimates By $0.06 EPS

Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) posted its quarterly earnings results on Thursday. The company reported ($0.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.65) by ($0.06), FiscalAI reports. The company had revenue of $11.71 million during the quarter. Senseonics Holdings, Inc. Common Stock had a negative return on equity of 111.78% and a negative net margin of 213.87%.

Here are the key takeaways from Senseonics Holdings, Inc. Common Stock’s conference call:

• Q1 commercial momentum: Net revenue was $11.7 million with a 58% gross margin, and management raised 2026 guidance to $60M–$64M, signaling early validation of the in‑house commercial model.
• U.S. commercial integration and channels: The Ascensia U.S. transition was described as seamless, direct‑to‑consumer new patient shipments accounted for ~60% of additions and nearly doubled YoY, and EonCare now performs over one‑third of insertions, supporting the company’s goal to double U.S. patients in 2026.
• Product pipeline progress: Senseonics is on track for Gemini in H1 2027 and plans a first‑in‑human trial for Freedom in H2 2026, while advancing app enhancements and manufacturing scale‑up.
• Financing strengthens runway: The company raised $92 million in equity and expanded its Hercules credit facility to $140 million (with an additional $20M drawn), providing capital to fund commercialization and next‑gen launches.
• Higher costs and cash burn: SG&A and operating expenses rose sharply (Q1 SG&A of $30.2M), net loss widened to $32.3M, and 2026 guidance implies $150M–$160M operating expenses and $110M–$120M cash utilization, indicating continued near‑term losses despite new financing.

Senseonics Holdings, Inc. Common Stock Price Performance

Shares of SENS traded down $0.33 during midday trading on Friday, hitting $5.03. The stock had a trading volume of 4,738,048 shares, compared to its average volume of 896,082. The firm has a 50 day moving average of $6.64. Senseonics Holdings, Inc. Common Stock has a twelve month low of $4.79 and a twelve month high of $14.50. The firm has a market capitalization of $210.20 million, a price-to-earnings ratio of -2.52 and a beta of 1.05. The company has a current ratio of 4.83, a quick ratio of 4.55 and a debt-to-equity ratio of 0.58.

Insider Activity

In other news, CEO Timothy T. Goodnow purchased 17,225 shares of the company’s stock in a transaction on Friday, March 13th. The shares were purchased at an average price of $5.79 per share, with a total value of $99,732.75. Following the purchase, the chief executive officer directly owned 651,243 shares of the company’s stock, valued at $3,770,696.97. This trade represents a 2.72% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Douglas A. Roeder purchased 17,500 shares of the company’s stock in a transaction on Friday, March 13th. The stock was purchased at an average cost of $5.73 per share, for a total transaction of $100,275.00. Following the purchase, the director directly owned 119,731 shares in the company, valued at approximately $686,058.63. This trade represents a 17.12% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Company insiders own 4.70% of the company’s stock.

Institutional Trading of Senseonics Holdings, Inc. Common Stock

Several hedge funds and other institutional investors have recently modified their holdings of SENS. First Light Asset Management LLC raised its stake in shares of Senseonics Holdings, Inc. Common Stock by 666.7% in the 2nd quarter. First Light Asset Management LLC now owns 35,708,124 shares of the company’s stock valued at $17,011,000 after purchasing an additional 31,050,619 shares during the period. UBS Group AG grew its holdings in shares of Senseonics Holdings, Inc. Common Stock by 409.0% in the 3rd quarter. UBS Group AG now owns 4,248,519 shares of the company’s stock valued at $1,852,000 after acquiring an additional 3,413,866 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Senseonics Holdings, Inc. Common Stock by 26.6% in the 2nd quarter. Geode Capital Management LLC now owns 8,701,129 shares of the company’s stock valued at $4,147,000 after acquiring an additional 1,828,302 shares in the last quarter. Sei Investments Co. bought a new position in shares of Senseonics Holdings, Inc. Common Stock in the 2nd quarter valued at about $761,000. Finally, Walleye Capital LLC bought a new position in shares of Senseonics Holdings, Inc. Common Stock in the 2nd quarter valued at about $539,000. Institutional investors and hedge funds own 12.36% of the company’s stock.

Wall Street Analysts Forecast Growth

SENS has been the topic of several research analyst reports. Weiss Ratings initiated coverage on Senseonics Holdings, Inc. Common Stock in a research note on Tuesday, February 17th. They set a “sell (d-)” rating on the stock. Stifel Nicolaus set a $9.00 price objective on Senseonics Holdings, Inc. Common Stock in a research note on Tuesday, March 3rd. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Senseonics Holdings, Inc. Common Stock presently has an average rating of “Moderate Buy” and a consensus price target of $18.38.

Senseonics Holdings, Inc. Common Stock Company Profile

Senseonics Holdings, Inc develops and commercializes long-term implantable continuous glucose monitoring (CGM) systems for people with diabetes. The company’s primary product family is the Eversense system, which combines a small subcutaneously implanted sensor, a removable external transmitter, and companion smartphone applications to provide continuous glucose readings and alerts. Senseonics positions its technology as an alternative to wearable patch-style CGMs by offering multi-month sensor longevity and on-body vibration alerts delivered through the transmitter.

Senseonics supports clinical and commercial activities that include research and development, regulatory engagement, manufacturing and distribution, and training for healthcare providers who perform sensor insertion and removal.